Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
News|Articles|September 14, 2023

Belong.Life Creates Conversational AI SaaS Solution to Support Cancer Clinical Trials

Solution designed to accelerate the process of matching patients with eligible clinical trials.

Belong.Life has officially launched Tara, a SaaS-based conversational AI cancer clinical trial matching platform for health providers and contract research organizations (CROs). According to the company, Tara is designed to accelerate the process of matching patients with eligible clinical trials, enabling increased recruitment at significantly lower costs. Following the launch of Dave, Tara is Belong’s second AI Health Mentor suite of solutions.

"Since our founding, Belong has provided clinical trial matching services to more than 30,000 patients," said Eliran Malki, CEO, co-founder, Belong.Life, in a company press release. "Tara is a natural extension of our services, helping to optimize clinical trial matching to benefit stakeholders with increased patient recruitment, improved randomization, and reduced costs and logistical challenges. Tara will enable more patients around the world to access clinical trials."

Reference: Belong.Life Launches New Conversational AI SaaS Solution for Cancer Clinical Trial Matching and Recruitment. PR Newswire. September 13, 2023. Accessed September 14, 2023. https://www.prnewswire.com/news-releases/belonglife-launches-new-conversational-ai-saas-solution-for-cancer-clinical-trial-matching-and-recruitment-301926197.html


Related to this article

© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.